glp-1 obesity drug market news today october 2025 Obesity GLP-1 Pharma Giants Bet on Next-Generation

Example Impacts: F&B Manufacturers: Demand for food and beverage may decrease in the future if the overall calorie consumption of the population drops as a result of the increased use of weight-loss drugs some analysts forecast a 1-3% overall reduction in calorie intake in the U.S

These medications are used for chronic weight management and treating type 2 diabetes

Addressing these limitations is crucial for enhancing the generalizability of findings or determining the necessity of race, gender, or agespecific investigations

Compared to the iGlar trial (insulin glargine U100), Japanese adults with T2D lost more weight in the iGlarLixi study (insulin glargine: Lixisenatide = 1:1)

Pancreatology 20, 12811286

M., Gonzalez-Campoy, J